Form 4: Indaptus Therapeutics Co-CEO Boosts Stake

Indaptus Therapeutics Co-Chief Executive Officer Jeffrey Meckler acquired 216,617 shares of common stock at $2.03 per share, increasing his total beneficial ownership to 229,929 shares.

Summary

• Jeffrey A. Meckler, Co-Chief Executive Officer, Director, and 10% Owner of Indaptus Therapeutics, Inc. (INDP), acquired 216,617 shares of common stock.
• The transaction occurred on December 22, 2025, at a price of $2.03 per share.
• This acquisition was made pursuant to an amendment to his employment agreement and in connection with a securities purchase agreement dated December 22, 2025.
• Following this transaction, Mr. Meckler beneficially owns a total of 229,929 shares of Indaptus Therapeutics common stock.

Sentiment

Score: 7

Explanation: The acquisition of a significant number of shares by a key insider (Co-CEO, Director, 10% Owner) is generally viewed as a positive signal, indicating strong confidence in the company's future prospects and valuation.

Positives

• Significant insider buying by a Co-CEO, Director, and 10% owner, signaling confidence in the company's future prospects.
• The acquisition was part of an employment agreement amendment, indicating a structured commitment from a key executive.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the insider acquisition may implicitly signal management's positive outlook on the company's future performance.

Management Comments

• The Reporting Person acquired 216,617 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025.

Industry Context

This insider transaction is specific to Indaptus Therapeutics and does not directly provide broader industry trends. However, insider buying can be a signal of confidence within the biotechnology or pharmaceutical sector, where company-specific developments often drive stock performance.

Related Party Transactions

• Jeffrey A. Meckler, Co-Chief Executive Officer, Director, and 10% Owner, acquired 216,617 shares of common stock from Indaptus Therapeutics, Inc. at $2.03 per share, pursuant to an amendment to his employment agreement and a securities purchase agreement.

Stakeholder Impact

• Shareholders may interpret the Co-CEO's significant share acquisition as a strong vote of confidence in the company's future, potentially leading to increased investor interest and positive sentiment.

Key Dates

Recommendation

The significant share acquisition by a key insider, who is both a Co-CEO, Director, and 10% owner, signals strong conviction in the company's intrinsic value and future growth potential. Such insider buying often precedes positive company developments and can be a strong indicator for investors to consider a 'buy' position, aligning with management's interests.

Keywords

Indaptus Therapeutics, INDP, Jeffrey Meckler, Insider Buying, Stock Acquisition, CEO, Director, 10% Owner, Employment Agreement, Securities Purchase Agreement